Article content
A Vancouver company is studying COVID-19 vaccine candidates that could be effective in controlling mutant strains now taking over the world.
According to a press release, Eyam Vaccines and Immunotherapeutics has started preclinical studies on the “efficacy of unique COVID-19 vaccine candidates that target SARS-CoV-2 variants.”
We apologize, but this video has failed to load.
Try refreshing your browser, or
Vancouver company in fight to identify COVID-19 variant-killing vaccine Back to video
The study is part of a joint venture licensing agreement struck last November with the University of B.C. to “develop several propriety COVID-19 vaccine candidates in a self-amplifying mRNA vaccine platform”.